In a prospective Chinese study in which bismuth was added to standard PPI-based triple therapy, the Helicobacter pylori eradication rate was above 90%. Increased treatment duration was also crucial—a therapeutic gain of 13% was achieved if the quadruple therapy was administered for 14 days instead of 7 days. Clarithromycin resistance was also overcome by the prolonged bismuth-containing quadruple therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sun, Q. et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial H. pylori eradication. Helicobacter 15, 233–238 (2010).
Mu, F., Hu, F., Yang, G. & Cheng, H. A clinical study of proton pump inhibitor-containing quadruple regimen as first-line therapy for H. pylori eradication. Chin. J. Gastroenterol. 12, 531–534 (2007).
Zheng, Q., Pan, Y., Zhang, L. & Xiao, S. Comparison of efficacy of 7-day rabeprazole-based triple therapy versus quadruple therapy for treatment of H. pylori infection. Chin. J. Gastroenterol. 11, 645–647 (2006).
Calvet, X., Gené, E., López, T. & Gisbert, J. P. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment. Pharmacol. Ther. 15, 1067–1076 (2001).
Fuccio, L. et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for H. pylori eradication. Ann. Intern. Med. 147, 553–562 (2007).
Zagari, R. M. et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for H. pylori eradication: The HYPER Study. Gut 56, 475–479 (2007).
Gatta, L., Vakil, N., Leandro, G., Di Mario, F. & Vaira D. Sequential therapy or triple therapy for H. pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 104, 3069–3079 (2009).
Moayyedi, P. & Malfertheiner, P. Editorial: Sequential therapy for eradication of H. pylori: a new guiding light or a false dawn? Am. J. Gastroenterol. 104, 3081–3083 (2009).
Malfertheiner, P. et al. Current concepts in the management of H. pylori infection: the Maastricht III Consensus Report. Gut 56, 772–781 (2007).
Laine, L. et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of H. pylori in duodenal ulcer patients: a prospective, randomized, mulicenter, North American trial. Am. J. Gastroenterol. 98, 562–567 (2003).
Goodwin, C. S. et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J. Clin. Pathol. 41, 207–210 (1988).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P. Malfertheiner has received grant/research support from Axcan and Novartis.
Rights and permissions
About this article
Cite this article
Malfertheiner, P. Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol 7, 538–539 (2010). https://doi.org/10.1038/nrgastro.2010.131
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.131
This article is cited by
-
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis
Drugs (2017)
-
Functional disruption of peroxiredoxin by bismuth antiulcer drugs attenuates Helicobacter pylori survival
JBIC Journal of Biological Inorganic Chemistry (2017)
